Bacteroides, Prevotella, and Porphyromonas species: A review of antibiotic resistance and therapeutic options

International Journal of Antimicrobial Agents

Volumn 15, Issue 1, 2000, Pages 1-9

  Falagas, Matthew E ^a,b,c   Siakavellas, Elias ^b  

^a HYGEIA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteroides; Epidemiology; Porphyromonas; Prevotella; Taxonomy; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CEFMETAZOLE; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; NALIDIXIC ACID; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPECTINOMYCIN; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIMENTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTEROIDES; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTEROIDES; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PORPHYROMONAS; PREVOTELLA;

EID: 0034035474     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00164-8     Document Type: Review

References (84)

1. Jousimies-Somer H.R., Summanen P.H., Finegold S.M. B. Porphyromonas, Prevotella, Fusibacterium, and other anaerobic Gram-negative bacteria. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H. Manual of Clinical Microbiology. 1995;American Society of Microbiology, Washington, DC.
2. Jousimies-Somer H.R. Update on the taxonomy and the clinical characteristics of pigmented Gram-negative rods. Clin. Infect. Dis. 20 Suppl. 2:1995;S187-S191.
3. Baron E.J., Curren M., Henderson H. et al. Bilophila wadsworthia. J. Clin. Microbiol. 30:1992;1882-1884.
4. Summanen P.H., Jousimies-Somer H.R., Manley S., Brucker D., Marina M., Goldstein E.J.C., Finegold S.M. Bilophila wadsworthia isolates from clinical specimens. Clin. Infect. Dis. 20, Suppl. 2:1995;S210-S211.
5. Wexler H.M., Reeves D., Summanen P.H. et al. Sutterella wadsworthensis gen. nov., sp. nov., bile-resistant microaerophilic Campylobacter gracilis-like clinical isolates. Int. J. Syst. Bacteriol. 461:1996;252-258.
6. Finegold S.M. Overview of clinically important anaerobes. Clin. Infect. Dis. 20, Suppl. 2:1995;S205-S207.
7. Vandamme P., Daneshvar M.I., Dewhirst F.E. et al. Chemotaxonomic analyses of B. gracilis and B. ureolyticus and reclassification of B. gracilis as Campylobacter gracilis comb. nov. Int. J. Syst. Bacteriol. 451:1995;145-152.
8. Paster B.J., Dewhirst F.E., Olsen I., Fraser G.J. Phylogeny of B. Prevotella, and Porphyromonas spp. and related bacteria. J. Bacteriol. 1763:1994;725-732.
9. Tanner A., Stillman N. Oral and dental infections with anaerobic bacteria: clinical features, predominant pathogens, and treatment. Clin. Infect. Dis. 16, Suppl. 4:1993;S304-S309.
10. Shordomo L., Barone A., Ramaglia L., Ciaglia R.N., Iacomo V.J. Antimicrobial susceptibility of periodontopathic bacteria associated with failing implants. J. Periodontol. 66:1995;69-74.
11. Takemoto T., Kurihara H., Dahlen G. Characterization of B. forsythus isolates. J. Clin. Microbiol. 35:1997;1378-1381.
12. Dosher C.W., Rosenblatt J.E., Wilson W.R., Ilstrup D.M. Anaerobic bacteremia: decreasing rate over a 15-year period. Rev. Infect. Dis. 13:1991;633-636.
13. Redondo M.C., Arbo M.D., Grindlinger J., Snydman D.R. Attributable mortality of bacteremia associated with B. fragilis group. Clin. Infect. Dis. 20:1995;1492-1496.
14. Snydman D.R., McDermott L., Cuchural G.L. et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of B. fragilis group species from 1990 to 1994. Clin. Infect. Dis. 23 Suppl. 1:1996;S54-S65.
15. Goldstein E.J., Citron D.M., Cherubin C.E., Hillier S.L. Comparative susceptibility of the B. fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin-sulbactam, clindamycin, and metronidazole. J. Antimicrob. Chemother. 31:1993;363-372.
16. Brook I. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the B. fragilis group. Rev. Infect. Dis. 13:1991;1170-1180.
17. Appleman M.D., Heseltine P.N.R., Cherubin C.E. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of B. fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center. Rev. Infect. Dis. 13:1991;12-18.
18. Duerden B.I. Role of reference laboratory in susceptibility testing of anaerobes and a survey of isolates referred from laboratories in England and Wales during 1993-1994. Clin. Infect. Dis. 20, Suppl. 2:1995;S180-S186.
19. Chen S.C., Gottlieb T., Palmer J.M., Morris G., Gilbert G.L. Antimicrobial susceptibility of anaerobic bacteria in Australia. J. Antimicrob. Chemother. 30:1992;811-820.
20. Westhuyzen I., Chalkley L.J. Antibiotic susceptibility of anaerobic bacteria isolated in Johannesburg. S. Afr. Med. J. 82:1992;314-317.
21. Dubreuil L., Breuil J., Dublanchet A., Seballian A. Survey of the susceptibility patterns of B. fragilis strains in France from to 1992. Eur. J. Clin. Microbiol. Infect. Dis. 1111:1977;1094-1099.
22. Tuner K., Nord C.E. Antibiotic susceptibility of anaerobic bacteria in Europe. Clin. Infect. Dis. 16, Suppl. 4:1993;S387-S389.
23. Turner P., Edwards R., Weston V., Gazis A., Ispahani P., Greenwood D. Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of B. fragilis. Lancet. 345:1995;1275-1277.
24. Goldstein E.J.C. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial ioslates in the United States. Clin. Infect. Dis. 16, Suppl. 4:1993;S377-S381.
25. Hecht D.W., Osmolski J.R. Comparison of activities of trovafloxacin CP-99,219 and five other agents against 585 anaerobes with use of three media. Clin. Infect. Dis. 23, Suppl. 1:1996;S44-S50.
26. Snydman D.R., MacDermott L. Analysis of the in vitro activity of trovafloxacin against Bacteroides species. Infect. Dis. Clin. Pract. 5 Suppl. 3:1996;S96-S100.
27. Niederau W., Hoffler U., Pulverer G. Susceptibility of B. melaninogenicus to 45 antibiotics. Chemotherapy. 26:1980;121-127.
28. Olsik B., Tenover F.C. Tetracycline resistance in periodontal pathogens. Clin. Infect. Dis. 16, Suppl. 4:1993;S310-313.
29. Sedallian A., Debrueres J. Frequency of isolation and antibiotic sensitivity of Bacteroides related to B. bivius and B. oralis. Pathol. Biol. 35:1987;586-589.
30. Brook I., Coolbaugh J.C., Walker R.I., Weiss E. Synergism between penicillin, clindamycin, or metronidazole and gentamicin against species of the B. melaninogenicus and B. fragilis groups. Antimicrob. Agents. Chemother. 25:1984;71-77.
31. Ralph E.D., Amatnieks Y.E. Potentially synergistic antimicrobial combinations with metronidazole against B. fragilis. Antimicrob. Agents Chemother. 17:1980;379-382.
32. Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in anaerobes. Clin Infect Dis 1997;24, Suppl. 1:S110-S120.
33. Appelbaum P.C. Patterns of resistance and resistance mechanisms in anaerobes. Clin. Microbiol. Newslett. 14:1992;49-56.
34. Nord C.E. Mechanisms of β-lactam resistance in anaerobic bacteria. Rev. Infect. Dis. Suppl. 8, Suppl. 5:1986;S543-S548.
35. Bush K. Metallo-beta-lactamases: a class apart. Clin. Infect. Dis. Suppl. 27, Suppl. 1:1998;S48-S53.
36. Edwards R., Greenwood D. Mechanisms responsible for reduced susceptibility to imipenem in B. fragilis. J. Antimicrob. Chemother. 38:1996;941-951.
37. Wexler H.M., Halebian S. Alterations to the penicillin-binding proteins in the B. fragilis group: a mechanism for non-β-lactamase mediated cefoxitin resistance. J. Antimicrob. Chemother. 26:1990;7-20.
38. Tally F.P., Cuchural G.J., Malamy M.H. Mechanisms of resistance and resistance transfer in anaerobic bacteria: factors influencing antimicrobial therapy. Rev. Infect. Dis. 6 Supppl. 1:1984;S260-S269.
39. Dalmau D., Cayouette M., Lamothe F. et al. Clindamycin resistance in the B. fragilis group: association with hospital-acquired infections. Clin. Infect. Dis. 24:1997;874-877.
40. Gorbach S.L. Antibiotic treatment of anaerobic infections. Clin. Infect. Dis. 18, Suppl. 4:1994;S305-S310.
41. Bartlett J.G. Antianaerobic antibacterial agents. Lancet. 2:1982;478-481.
42. Falagas M.E., McDermott L., Snydman D.R. The effect of pH on in vitro antimicrobial susceptibility of B. fragilis group. Antimicrob. Agents. Chemother. 41:1997;2047-2049.
43. Bryan C.S., Reynolds K.L., Kirkhart B., Brown J. Bacteroides bacteremia. Arch. Surg. 119:1984;894-898.
44. Vasquez F., Mendez F.J., Perez F., Mendoza M.C. Anaerobic bacteremia in a general hospital: retrospective five-year analysis. Rev. Infect. Dis. 95:1987;1038-1043.
45. Westerman T., Panzer J.D., Atkinson W.H. Comparative efficacy of clindamycin HCl and tetracycline HCl in acute sinusitis. Ear Nose Throat J. 546:1975;236-238.
46. Brook I. Clindamycin in treatment of chronic recurrent suppurative otitis media in children. J. Laryngol. Otol. 946:1980;607-615.
47. Gudiol F., Manresa F., Pallares R. et al. Clindamycin vs. penicillin for anaerobic lung infections. Arch. Intern. Med. 150:1990;2525-2529.
48. Egwari L.O., Rotimi V.O., Coker A.O. Antibiotic susceptibility of clinical isolates of Prevotella bivia in Lagos, Nigeria. J. Chemother. 81:1996;47-51.
49. Brook I., Calhoun L., Yokum P. Beta-lactamase producing isolates of B. species from children. Antimicrob. Agents Chemother. 18:1980;164-165.
50. Levison M.E., Mangura C.T., Lorber B. et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. An. Intern. Med. 984:1983;466-471.
51. Ferguson A.D., Prescott R.J., Selkon J.B., Watson D., Swinburn C.R. The clinical course and management of thoracic empyema. Quart. J. Med. 89:1996;285-289.
52. Kelly W., Morris M.J. Empyema thoracis: medical aspects of evaluation and treatment. South. Med. J. 8711:1994;1103-1110.
53. Bartlett J.G. Bacterial infections of the pleural space. Semin. Respir. Infect. 3:1988;308-321.
54. Sadigh M., Wassef W. Parapneumonic effusions and empyema. Cur. Opin. Infect. Dis. 3:1990;189-194.
55. Orringer M.B. Thoracic empyema-back to basics. Chest. 93:1988;901-902.
56. Falagas M.E., Gorbach S.L. Clindamycin and metronidazole. Med. Clin. North. Am. 794:1995;845-867.
57. Bartlett J.G. Intraabdominal sepsis. Med. Clin. North. Am. 793:1995;599-615.
58. Heseltine PNR, Yellin AE, Appleman MD et al. Perforated and gangrenous appendicitis: an analysis of antibiotic failures. J Infect Dis 1983;1482:322-329.
59. Nichols R.L., Smith J.W. Wound and intraabdominal infections: microbiological considerations and approaches to treatment. Clin. Infect. Dis. Suppl. 4:1993;S266-272.
60. Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem/cilastatin versus gentamycin and clindamycin in mixed flora infections. Am J Med 1985;78, Suppl. 6A:85-91.
61. Garber G.E., Chow A.W. Female genital tract infections. Finegold S.M., Lance George W. Anaerobic Infections in Humans. 1989;Academic Press, CA.
62. Pitkin D., Sheikh W., Wilson S. et al. Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic and skin and soft tissue infections. Clin. Infect. Dis. 202:1995;S372-S377.
63. Soriano F., Aguado J.M., Tornero J., Fernandez-Guerrero M.L., Gómez-Garcés J.L. B. fragilis meningitis successfully treated with metronidazole after a previous failure with thiamphenicol. J. Clin. Microbiol. 243:1986;472-473.
64. Feder H.M. Jr B. fragilis meningitis. Rev. Infect. Dis. 94:1987;783-786.
65. Sjolin J., Lilja A., Eriksson N., Arneborn P., Cars O. Treatment of brain abscess with cefotaxime and metronidazole: prospective study on 15 consecutive patients. Clin. Infect. Dis. 175:1993;857-863.
66. Boom W.H., Tuazon C.U. Successful treatment of multiple brain abscesses with antibiotics alone. Rev. Infect. Dis. 72:1985;189-199.
67. File T.M. Jr, Tan J.S. Treatment of skin and soft-tissue infections. Am. J. Surg. 169 Suppl. 5A:1995;27S-33.
68. Tassler H., Cullmann W., Eldhart D. Therapy of soft tissue infections with piperacillin/tazobactam. J. Antimicrob. Chemother. Suppl. A31:1993;105-112.
69. Marier R.L. Role of imipenem/cilastatin in the treatment of soft tissue infections. Am. J. Med. 786A:1985;140-144.
70. Nichols R.L., Smith J.W., Geckler R.W., Wilson S.E. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections published erratum appears in South Med J;886:634. South. Med. J. 884:1995;397-404.
71. Loesche W.J., Giordano J.R., Hujoel P., Schwartz J., Smith B.A. Metronidazole in periodontitis: reduced need for surgery. J. Clin. Periodontol. 192:1992;103-112.
72. van Winkelhoff, Abbas F, Pavicic MJA, de Graaf J. Chronic conjunctivitis caused by oral anaerobes and effectively treated with systemic metronidazole plus amoxicillin. J Clin Microbiol 1991;294:723-725.
73. Gordon J., Walker C., Hovliaras C., Socransky S. Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results. J. Periodontol. 6111:1990;686-691.
74. Dickie A.S. Current concepts in the management of infections in bones and joints. Drugs. 32:1986;458-475.
75. Rosenkranz P., Lederman M.M., Gopalakrishna K.V., Ellner J.J. Septic arthritis caused by B. fragilis. Rev. Infect. Dis. 121:1990;20-30.
76. Johnson C.C., Reinhardt J.F., Wallace S.L. et al. Safety and efficacy of ticarcillin plus clavulanic acid in the treatment of infections of soft tissue, bone and joint. Am. J. Med. 79 Suppl. 5B:1985;136-140.
77. Goldstein E.J.C., Citron D.M. Susceptibility testing of anaerobes-fact, fancy, and wishful thinking. Clin. Ther. 11:1989;710-723.
78. Wexler H.M. Susceptibility testing of anaerobic bacteria - the state of the art. Clin. Infect. Dis. 16 Suppl. 4:1993;S328-S333.
79. Rosenblatt J.E., Brook I. Clinical relevance of susceptibility of anaerobic bacteria. Clin. Infect. Dis. 16 Suppl. 4:1993;S446-S448.
80. Hecht D.W., Lederer L. Effect of choice of medium on the results of in vitro susceptibility testing of eight antibiotics against the B. fragilis group. Clin. Infect. Dis. 20 Suppl. 2:1995;S346-S349.
81. Snydman DR, Cuchural GJ Jr., McDermott L, Gill M. Correlation of various in vitro testing methods with clinical outcomes in patients with B. fragilis group infections treated with cefoxitin. A retrospective analysis. Antimicrob Agents Chemother 1992;36:540-544.
82. Sheikh W., Bodey D.G. Lack of predictability of cefotetan in vitro susceptibility tests against cefotetan-resistant anaerobic bacteria in determining clinical and bacteriologic efficacies. Diagn. Microbiol. Infect. Dis. 15:1992;595-600.
83. Edwards R. Resistance to beta-lactam antibiotics in B. spp. J. Med. Microbiol. 4612:1997;979-986.
84. Lee K. Antimicrobial resistance patterns of B. fragilis group in Korea. Yonsei Med. J. 396:1998;578-586.